Trusts scholar contributes to new Cambridge spin-out company

Research carried out by a team at the Anne McLaren Laboratory for Regenerative Medicine has developed the technology to generate human liver cells for commercial use.  The team includes Candy Hsin-Hua Cho, who was supported during her PhD studies in Cambridge by the Cambridge Overseas Trust.

The spin-out company DefiniGEN will develop cells, originally derived from stem cells in patients’ skin, to be used in work on drug discovery and regenerative medicine.  Other work undertaken by the company will provide stem cells for research into treatments for diseases such as diabetes.

See the Cambridge Enterprise website for a fuller account of the research and its implications. 

Differentiation of human Induced Pluripotent Stem Cells (hIPSC) to functional liver hepatocyte cells (Credit: Ludovic Vallier)

Differentiation of human Induced Pluripotent Stem Cells (hIPSC) to functional liver hepatocyte cells (Credit: Ludovic Vallier)